Historical Valuation
Strata Critical Medical Inc (SRTA) is now in the Fair zone, suggesting that its current forward PS ratio of 1.07 is considered Fairly compared with the five-year average of -16.78. The fair price of Strata Critical Medical Inc (SRTA) is between 5.66 to 8.16 according to relative valuation methord.
Relative Value
Fair Zone
5.66-8.16
Current Price：5.73
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Strata Critical Medical Inc (SRTA) has a current Price-to-Book (P/B) ratio of 1.50. Compared to its 3-year average P/B ratio of 1.54 , the current P/B ratio is approximately -2.52% higher. Relative to its 5-year average P/B ratio of 1.54, the current P/B ratio is about -2.52% higher. Strata Critical Medical Inc (SRTA) has a Forward Free Cash Flow (FCF) yield of approximately -12.85%. Compared to its 3-year average FCF yield of -9.85%, the current FCF yield is approximately 30.47% lower. Relative to its 5-year average FCF yield of -9.85% , the current FCF yield is about 30.47% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for SRTA competitors is 1.09, providing a benchmark for relative valuation. Strata Critical Medical Inc Corp (SRTA.O) exhibits a P/S ratio of 1.07, which is -2.3% above the industry average. Given its robust revenue growth of 36.70%, this premium appears sustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of SRTA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SRTA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SRTA currently overvalued or undervalued?
Strata Critical Medical Inc (SRTA) is now in the Fair zone, suggesting that its current forward PS ratio of 1.07 is considered Fairly compared with the five-year average of -16.78. The fair price of Strata Critical Medical Inc (SRTA) is between 5.66 to 8.16 according to relative valuation methord.
What is Strata Critical Medical Inc (SRTA) fair value?
SRTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Strata Critical Medical Inc (SRTA) is between 5.66 to 8.16 according to relative valuation methord.
How does SRTA's valuation metrics compare to the industry average?
The average P/S ratio for SRTA's competitors is 1.09, providing a benchmark for relative valuation. Strata Critical Medical Inc Corp (SRTA) exhibits a P/S ratio of 1.07, which is -2.30% above the industry average. Given its robust revenue growth of 36.70%, this premium appears sustainable.
What is the current P/B ratio for Strata Critical Medical Inc (SRTA) as of Jan 16 2026?
As of Jan 16 2026, Strata Critical Medical Inc (SRTA) has a P/B ratio of 1.50. This indicates that the market values SRTA at 1.50 times its book value.
What is the current FCF Yield for Strata Critical Medical Inc (SRTA) as of Jan 16 2026?
As of Jan 16 2026, Strata Critical Medical Inc (SRTA) has a FCF Yield of -12.85%. This means that for every dollar of Strata Critical Medical Inc’s market capitalization, the company generates -12.85 cents in free cash flow.
What is the current Forward P/E ratio for Strata Critical Medical Inc (SRTA) as of Jan 16 2026?
As of Jan 16 2026, Strata Critical Medical Inc (SRTA) has a Forward P/E ratio of 7.70. This means the market is willing to pay $7.70 for every dollar of Strata Critical Medical Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Strata Critical Medical Inc (SRTA) as of Jan 16 2026?
As of Jan 16 2026, Strata Critical Medical Inc (SRTA) has a Forward P/S ratio of 1.07. This means the market is valuing SRTA at $1.07 for every dollar of expected revenue over the next 12 months.